New Delhi: In a decisive move to widen access to obesity care, Danish pharmaceutical major Novo Nordisk has announced a 37 percent reduction in the Indian pricing of its once-weekly injectable medicine, Wegovy, targeting chronic weight management.
Launched in India in June 2025, Wegovy is now available at significantly lower monthly rates across all its dose strengths. The lowest dose (0.25 mg) will now retail at Rs 10,850 per monthly pack (down from Rs 16,260.94), while the highest dose (2.4 mg) will cost Rs 16,400, down from about Rs 24,389.06.
India faces a growing burden of overweight and obesity: data from the National Family Health Survey (NFHS‑5) show that nearly one in four Indian adults is overweight or obese, particularly in urban settings. Experts say that while lifestyle changes remain fundamental, medically guided treatments like GLP-1 receptor agonists (the class to which Wegovy belongs) are increasingly critical for individuals whose efforts via diet and exercise have plateaued.
Wegovy works by mimicking a hormone that controls appetite, helping users reduce food intake and lose weight when combined with healthy lifestyle choices. Clinical trials globally have shown roughly 20 % weight loss in up to one-third of users.
By lowering the cost of entry, Novo Nordisk hopes the reduced pricing will empower more patients in India to take proactive steps in managing their weight and associated cardiovascular risk factors.
